Prestige Biologics Co., Ltd. (KOSDAQ:334970)

Prestige Biologics Revenue

In the fiscal year ending June 30, 2025, Prestige Biologics had annual revenue of 12.53B KRW with 477.83% growth. Prestige Biologics had revenue of 5.69B in the quarter ending June 30, 2025, a decrease of -4,310.74%.

• Revenue: 12.53B
• Revenue Growth: +477.83%
• P/S Ratio: 42.29
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 283.80B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2025	12.53B	10.36B	477.83%
Jun 30, 2024	2.17B	423.21M	24.24%
Jun 30, 2023	1.75B	1.73B	11,115.88%
Dec 31, 2022	15.57M	-3.21B	-99.52%
Dec 31, 2021	3.23B	-	-